Coagulation products and their uses.
Article Details
- CitationCopy to clipboard
Shord SS, Lindley CM
Coagulation products and their uses.
Am J Health Syst Pharm. 2000 Aug 1;57(15):1403-17; quiz 1418-20.
- PubMed ID
- 10938981 [ View in PubMed]
- Abstract
The indications, pharmacokinetics, and therapeutic guidelines for available coagulation products are reviewed. Patients with hemophilia, von Willebrand's disease (VWD), or acquired inhibitors to antihemophilic factor (AHF) cannot spontaneously stop an acute hemorrhage. Coagulation products used to manage bleeding in patients with these disorders include AHF concentrates, factor IX concentrates, factor VIIa concentrate, factor IX complexes, anti-inhibitor coagulant complexes, and desmopressin acetate. Typically, these commercially available products are used to manage acute bleeding or to prevent excessive bleeding during surgery. The dosage of the coagulation products and the duration of therapy depend on many variables, including the severity of the hemorrhage, the pharmacokinetics of the coagulation products, and patient-specific factors. Product purity and viral attenuation are also important considerations in determining an appropriate dosage regimen. Recombinant versions of some coagulant factors are available and can eliminate the risk of viral transmission. A thorough understanding of each coagulation product can guide product selection, dosing, and treatment duration and can reduce the risk of viral transmission.
DrugBank Data that Cites this Article
- Drug Targets
Drug Target Kind Organism Pharmacological Action Actions Antihemophilic factor, human recombinant von Willebrand factor Protein Humans YesBinderDetails Coagulation Factor IX (Recombinant) Coagulation factor VII Protein Humans YesLigandDetails Coagulation Factor IX Human Coagulation factor VII Protein Humans YesLigandDetails Lonoctocog alfa von Willebrand factor Protein Humans YesBinderDetails Moroctocog alfa von Willebrand factor Protein Humans YesBinderDetails